{"id":"evolocumab-and-ldl-apheresis","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2364655","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, evolocumab prevents it from returning to the liver, where it would normally stimulate the production of LDL cholesterol. This leads to a decrease in LDL cholesterol levels in the blood, which can help to reduce the risk of cardiovascular events. LDL apheresis, on the other hand, is a procedure that directly removes LDL cholesterol from the blood.","oneSentence":"Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:55.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Homozygous familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT01624142","phase":"PHASE2, PHASE3","title":"Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-06-01","conditions":"Severe Familial Hypercholesterolemia","enrollment":300},{"nctId":"NCT02585895","phase":"PHASE3","title":"Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-12-21","conditions":"Hypercholesterolemia","enrollment":39},{"nctId":"NCT03429998","phase":"PHASE3","title":"Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2017-04-01","conditions":"Hypercholesterolemia","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"evolocumab and LDL apheresis","genericName":"evolocumab and LDL apheresis","companyName":"Hospital General Universitario Gregorio Marañon","companyId":"hospital-general-universitario-gregorio-mara-on","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver. Used for Hypercholesterolemia, Homozygous familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}